It is concerning that emerging variants of SARS-CoV-2 can evade neutralising antibodies
induced by previous infection or vaccination through mutations in the spike protein …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Although WHO has declared an end to the emergency phase of the COVID-19 pandemic,
SARS-CoV-2 has continued to spread and evolve, giving rise to new variants. 1 These new …

Several studies have shown that neutralising antibody level is a good biomarker for the
correlate of protection against SARS-CoV-2 infection. 1–3 However, results from these …

SARS-CoV-2 variants, particularly the recently emerged delta (B. 1.617. 2) variant, have
caused another wave of infection worldwide. 1, 2 Whether these variants are sensitive to the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …

Background Mutations accrued by SARS-CoV-2 lineage P. 1—first detected in Brazil in early
January, 2021—include amino acid changes in the receptor-binding domain of the viral …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

2 Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 lambda variant exhibits enhanced
infectivity and immune resistance. Cell Rep 2022; 38: 110218. 3 Bruel T, Hadjadj J, Maes P …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …